Skip to main content
SpringerLink
Log in

Standard Therapeutic Approach and New Therapies

  • Chapter
  • First Online:
Crohn’s Disease

  • 1250 Accesses

Abstract

The traditional approach to therapy of Crohn’s disease has been the step-up approach usually represented as a pyramid (Fig. 7.1) where, progressing from mild to severe disease, therapeutic choices proceed step by step from less potent drugs at the basement of the pyramid to more potent but also more toxic drugs at the top. The advent of biological therapies and the wider use of immunomodulators, together with the opportunity to achieve ambitious treatment goals and possibly to modify the course of disease, have led to other approaches such as the accelerated step-up or the top-down approach. This means that immunomodulators and biologics can be used earlier and de-escalated when disease is in deep remission. This could allow prolonged remission.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. D′Haens G, Baert F, van Assche G, et al., for the Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet. 2008;371:660–7.

    Google Scholar 

  2. Gert Van Assche, Axel Dignass, Julian Panes, Laurent Beaugerie et al. for the European Crohn's and Colitis Organisation (ECCO). The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. J Crohns Colitis. 2010;4:7–27.

    Google Scholar 

  3. Dignass A, Van Assche G, Lindsay JO, Lémann M, et al. for the European Crohn’s and Colitis Organisation (ECCO). The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: Current management. J Crohns Colitis. 2010;4: 28–62.

    Google Scholar 

  4. Gert Van Assche, Axel Dignass, Walter Reinisch, et al. for the European Crohn’s and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: special situations. J Crohns Colitis. 2010;4:63–101.

    Google Scholar 

  5. Best WR, Becktel JM, Singleton JW, Kern Jr F. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70:439–44.

    CAS  PubMed  Google Scholar 

  6. Harvey FR, Bradshaw JM. A simple index of Crohn’s disease activity. Lancet. 1980;1:514.

    Article  CAS  PubMed  Google Scholar 

  7. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn’s Relapse Prevention Trial Study Group. Gastroenterology. 1994;106:287–96.

    Article  CAS  PubMed  Google Scholar 

  8. Kiss LS, Papp M, Lovasz BD, et al. High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn’s disease: a marker for patient classification? Inflamm Bowel Dis. 2012;18(9):1647–54.

    Article  PubMed  Google Scholar 

  9. Sipponen T, Karkkainen P, Savilahti E, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings. Aliment Pharmacol Ther. 2008;28(10):1221–9.

    Article  CAS  PubMed  Google Scholar 

  10. Sipponen T, Savilahti E, Kohlo KL, Nuutinen H, Turunen U, Farkkila M. Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008;14(1):40–6.

    Article  PubMed  Google Scholar 

  11. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective multicentre study. Grouped’EtudesTherapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut. 1989;30(7):983–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Daperno M, D’Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 2004;60(4):505–12.

    Article  PubMed  Google Scholar 

  13. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. 1990;99(4):956–63.

    Article  CAS  PubMed  Google Scholar 

  14. Ferrante M, Colombel JF, Sandborn WJ, et al. International Organization for the Study of Inflammatory Bowel Diseases. Validation of endoscopic activity scores in patients with Crohn’s disease based on a post hoc analysis of data from SONIC. Gastroenterology. 2013;145(5):978–86.

    Google Scholar 

  15. Maconi G, Radice E, Greco S, Bianchi Porro G. Bowel ultrasound in Crohn’s disease. Best Pract Res Clin Gastroenterol. 2006;20(1):93–112.

    Article  PubMed  Google Scholar 

  16. Di Mizio R, Maconi G, Romano S, D’Amario F, Bianchi Porro G, Grassi R. Small bowel Crohn disease: sonographic features. Abdom Imaging. 2004;29(1):23–35.

    Article  PubMed  Google Scholar 

  17. Panes J, Bouhnik Y, Reinisch W, et al. Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. J Crohns Colitis. 2013;7(7):556–85.

    Article  CAS  PubMed  Google Scholar 

  18. Makanyanga JC, Taylor SA. Current and future role of MR enterography in the management of Crohn disease. AJR Am J Roentgenol. 2013;201(1):56–64.

    Article  PubMed  Google Scholar 

  19. Hommes D, Colombel JF, Emery P, Greco M, Sandborn WJ. Changing Crohn’s disease management: need for new goals and indices to prevent disability and improve quality of life. J Crohns Colitis. 2012;6 Suppl 2:S224–34.

    Article  PubMed  Google Scholar 

  20. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease. Inflamm Bowel Dis. 2009;15(9):1295–301.

    Article  PubMed  Google Scholar 

  21. Baert F, Moortgat L, Van Assche G, et al. Belgian Inflammatory Bowel Disease Research Group. North-Holland Gut Club Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology. 2010;138(2):463–8.

    Google Scholar 

  22. Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K. Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol. 2000;95(12):3452–7.

    CAS  PubMed  Google Scholar 

  23. Haskó G, Szabó C, Németh ZH, Deitch EA. Sulphasalazine inhibits macrophage activation: inhibitory effects on inducible nitric oxide synthase expression, interleukin-12 production and major histocompatibility complex II expression. Immunology. 2001;103(4):473–8.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology. 1999;116(3):602–9.

    Article  CAS  PubMed  Google Scholar 

  25. Tremaine WJ, Schroeder KW, Harrison JM, Zinsmeister AR. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn’s colitis and ileocolitis. J Clin Gastroenterol. 1994;19:278–82.

    Article  CAS  PubMed  Google Scholar 

  26. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn’s disease: results of a 16-week trial. Gastroenterology. 1993;104:1293–301.

    Article  CAS  PubMed  Google Scholar 

  27. Ford AC, Khan KJ, Talley NJ, Moayyedi P. 5-aminosalicylates prevent relapse of Crohn’s disease after surgically induced remission: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(3):413–20.

    Article  CAS  PubMed  Google Scholar 

  28. Cammá C, Giunta M, Roselli M, et al. Mesalamine in the maintenance treatment of Crohn’s disease: a meta-analysis adjusted for confounding variables. Gastroenterology. 1997;113:1465–73.

    Article  PubMed  Google Scholar 

  29. Feagan BG. Editorial: 5-ASA therapy for active Crohn’s disease: old friends, old data and a new conclusion. Clin Gastroenterol Hepatol. 2004;2:376–8.

    Article  PubMed  Google Scholar 

  30. Ransford RAJ, Langman MJS. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut. 2002;51:536–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Summers RW, Switz DM, Sessions JT, et al. National cooperative Crohn’s disease study group: results of drug treatment. Gastroenterology. 1979;77:847–69.

    CAS  PubMed  Google Scholar 

  32. Malchow H, Ewe K, Brandes JW, et al. European co-operative Crohn’s disease study (ECCDS): results of drug treatment. Gastroenterology. 1984;86:249–66.

    CAS  PubMed  Google Scholar 

  33. Otley A, Steinhart AH. Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2005;(4):CD000296. Review.

    Google Scholar 

  34. Benchimol EI, Seow CH, Otley AR, Steinhart AH. Budesonide for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2009;(1):CD002913.

    Google Scholar 

  35. Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO. Corticosteroids for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev. 2003;(4):CD000301.

    Google Scholar 

  36. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621–30.

    Article  CAS  PubMed  Google Scholar 

  37. Toruner M, Loftus EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929–36.

    Article  PubMed  Google Scholar 

  38. British Society of Gastroenterology. Guidelines for osteoporosis in celiac disease and inflammatory bowel disease. Gut. 2000;46(Suppl1):i1–8.

    Google Scholar 

  39. Compston J. Osteoporosis in inflammatory bowel disease. Gut. 2003;52:63–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Arnold GL, Beaves MR, Pryjdun VO, Mook WJ. Preliminary study of ciprofloxacin in active Crohn’s disease. Inflamm Bowel Dis. 2002;8:10–5.

    Article  PubMed  Google Scholar 

  41. Sutherland L, Singleton J, Sessions J, Hanauer S, Krawitt E, Rankin G, Summers R, et al. Double blind, placebo-controlled trial of metronidazole in Crohn’s disease. Gut. 1991;32:1071–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Thia KT, Mahadevan U, Feagan BG, et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn’s disease: a randomized, double-blind, placebo controlled pilot study. Inflamm Bowel Dis. 2009;15(1):17–24.

    Article  PubMed  Google Scholar 

  43. Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, Kerremans R. Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology. 1995;108:1617–21.

    Article  CAS  PubMed  Google Scholar 

  44. Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn’s disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol. 1996;91:328–32.

    CAS  PubMed  Google Scholar 

  45. Borgaonkar MR, MacIntosh DG, Fardy JM. A meta-analysis of anti-mycobacterial therapy for Crohn’s disease. Am J Gastroenterol. 2000;95:725–9.

    Article  CAS  PubMed  Google Scholar 

  46. Shafran I, Burgunder P. Adjunctive antibiotic therapy with rifaximin may help reduce Crohn’s disease activity. Dig Dis Sci. 2010;4:1079–84.

    Article  Google Scholar 

  47. Maltzman JS, Koretzky GA. Azathioprine: old drug, new actions. J Clin Invest. 2003;111(8):1122–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4þ T lymphocytes. J Clin Invest. 2003;111(8):1133–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Sandborn WJ, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease. Cochrane Database Syst Rev. 2000;(2):CD000545.

    Google Scholar 

  50. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev. 2000;(2):CD000067.

    Google Scholar 

  51. Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M. Azathioprineor 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2009;(1):CD000067.

    Google Scholar 

  52. Reinisch W, Angelberger S, Petritsch W, Shonova O, Lukas M, Bar-Meir S, et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn’s disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut. 2010;59:752–9.

    Article  CAS  PubMed  Google Scholar 

  53. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 years review. Gut. 2002;50:485–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Nielsen OH, Vainer B, Rask-Madsen J. Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther. 2001;15:1699–708.

    Article  CAS  PubMed  Google Scholar 

  55. Al Hadithy AFY, de Boer NKH, Derijks LJJ, Escher JC, Mulder CJ, Brouwers JR. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations. Dig Liver Dis. 2005;37:282–97.

    Article  CAS  PubMed  Google Scholar 

  56. Connel WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut. 1993;34:1081–5.

    Article  Google Scholar 

  57. Beaugerie L, Brousse N, Bouvier AM, CESAME Study Group, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374(9701):1617–25.

    Article  CAS  PubMed  Google Scholar 

  58. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Cesame Study Group, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011;141(5):1621–8. e1–e5.

    Article  CAS  PubMed  Google Scholar 

  59. Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Risk of melanoma and non melanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143(2):390–9.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Singh H, Nugent Z, Demers AA, Bernstein CN. Increased risk of non-melanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology. 2011;141(5):1612–20.

    Article  PubMed  Google Scholar 

  61. Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010;8(3):268–74.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Rahier aF, Magrob cd, Abreue C, ArmuzziA, f Ben-Horing S, Chowers Y, h M. et al. on behalf of the European Crohn’s and Colitis Organisation (ECCO). Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease J.F. J Crohns Colitis. 2014;8:443–68.

    Google Scholar 

  63. Pittet V, Froehlich F, Maillard MH, EPACT-II Update Panelists. When do we dare to stop biological or immunomodulator therapy for Crohn’s disease? Results of a multidisciplinary European expert panel. J Crohns Colitis. 2013;7:820–926.

    Article  PubMed  Google Scholar 

  64. Fraser AG. Methotrexate: first or second-line immunomodulator? Eur J Gastroenterol Hepatol. 2003;15:225–31.

    Article  CAS  PubMed  Google Scholar 

  65. Feagan BG, Fedorak RN, Irvine EJ, et al; North American Crohn’s Study Group Investigators. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. N Engl J Med. 2000;342(22):1627–32.

    Google Scholar 

  66. Te HS, Schiano TD, Kuan SF, et al. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol. 2000;95:3150–6.

    Article  CAS  PubMed  Google Scholar 

  67. van der Woude CJ, Ardizzone S, Bengtson MB, Fiorino G, Fraser G, Katsamos K, Kolacek S, Juillerat P, Mulders AGMJ, Pedersen N, Selinger C, Sebastian S, Sturm A, Zelinova Z, Magro F, for the European Crohn’s and Colitis Organization (ECCO). The second European evidence- based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015;9:107–24.1–18.

    Google Scholar 

  68. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease. Gastroenterology. 2003;124(7):1774–85.

    Article  PubMed  Google Scholar 

  69. Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn’s disease. Gut. 2002;50(2):206–11.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Orlando A, et al. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. Dig Liver Dis. 2010;43:1–20.

    Article  PubMed  Google Scholar 

  71. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009;58:501–8.

    Article  CAS  PubMed  Google Scholar 

  72. Panaccione R, Colombel JF, Sandborn WJ, et al. Adalimumab sustains clini- cal remission and overall clinical benefit after 2 years of therapy for Crohn’s disease. Aliment Pharmacol Ther. 2010;31:1296–309.

    Google Scholar 

  73. Louis E, Vernier-Massouille G, Grimaud JC, et al. Infliximab discontinuation in Crohn’s disease patients in stable remission on combined therapy with immunosuppressors: interim analysis of a prospective cohort study. Gut. 2008;57(Supp 2):A66.

    Google Scholar 

  74. Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al. A pooled analysis of infections, malignancy, and mortality in infliximab and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107(7):1051–63.

    Google Scholar 

  75. Sandborn W, Rutgeerts P, Reinisch W, et al. Study of biologic and immunomodulator naive patients in Crohn’s disease (SONIC). Presented at the annual scientific meeting of the American College of Gastroenterology, Orlando; 7 Oct 2008.

    Google Scholar 

  76. Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo- controlled trials. Clin Gastroenterol Hepatol. 2008;6:644–53.

    Article  CAS  PubMed  Google Scholar 

  77. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275–85.

    Article  CAS  PubMed  Google Scholar 

  78. Shale M, Kanfer E, Panaccione R, et al. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut. 2008;57:1639–41.

    Article  PubMed  Google Scholar 

  79. Ochenrider MG, Patterson DJ, Aboulafia DM. Hepatosplenic T-cell lymphoma in a young man with Crohn’s disease: casa report and literature review. Clin Lymphoma Myeloma Leuk. 2010;10(2):144–8.

    Google Scholar 

  80. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med. 1997;337:1029–35.

    Article  CAS  PubMed  Google Scholar 

  81. Hanauer SB, Feagan BG, Lichtenstein GR, et al; ACCENT I Study Group. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–9.

    Google Scholar 

  82. Sands BE, Blank MA, Patel K, van Deventer SJ, ACCENT II Study. Long-term treatment of rectovaginal fistulas in Crohn’s disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol. 2004;2(10):912–20.

    Article  CAS  PubMed  Google Scholar 

  83. Colombel JF, Sandborn WJ, Reinisch W, SONIC Study Group, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–95.

    Article  CAS  PubMed  Google Scholar 

  84. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350:876–85.

    Article  CAS  PubMed  Google Scholar 

  85. Hanauer SB, Rutgeerts PJ, D’Haens G, et al. Delayed hypersensitivity to infliximab (Remicade) re-infusion after 2–4 year interval without treatment. Gastroenterology. 1999;116:A731.

    Google Scholar 

  86. Cvetkovic R, Scott L. Adalimumab: a review of its use in adult patients with rheumatoid arthritis. BioDrugs. 2006;20:293–311.

    Article  CAS  PubMed  Google Scholar 

  87. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323–33. quiz 591.

    Article  CAS  PubMed  Google Scholar 

  88. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 2007;56(9):1232–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132(1):52–65.

    Article  CAS  PubMed  Google Scholar 

  90. Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007;13:1323–32.

    Article  PubMed  Google Scholar 

  91. Sandborn W, Feagan B, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med. 2007;357:228–38.

    Article  CAS  PubMed  Google Scholar 

  92. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med. 2007;357:239–50.

    Article  CAS  PubMed  Google Scholar 

  93. Clifford D, De Luca A, Simpson D, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010;9:438–46.

    Article  CAS  PubMed  Google Scholar 

  94. Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009;330:864–75.

    Article  CAS  PubMed  Google Scholar 

  95. Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711.

    Article  CAS  PubMed  Google Scholar 

  96. Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut. 2012;61:918e932.

    Article  Google Scholar 

  97. Sandborn WJ, Gasink C, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012;367:1519–28.

    Article  CAS  PubMed  Google Scholar 

  98. Sandborn WJ, Ghosh S, Panes J, et al. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2014;12(9):1485–93.

    Article  CAS  PubMed  Google Scholar 

  99. Monteleone G, Neurath MF, Ardizzone S, et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn’s disease. N Engl J Med. 2015;372(12):1104–13.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gastroenterology Section, DiBiMis, University of Palermo, Palermo, Italy

    Marco Mendolaro, Anna Viola & Maria Cappello

Authors
  1. Marco Mendolaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anna Viola
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria Cappello
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria Cappello .

Editor information

Editors and Affiliations

  1. Radiology Department, Policlinico Paolo Giaccone, Palermo, Italy

    Giuseppe Lo Re

  2. Radiology Department, University of Palermo, Policlinico Paolo Giaccone, Palermo, Italy

    Massimo Midiri

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Mendolaro, M., Viola, A., Cappello, M. (2016). Standard Therapeutic Approach and New Therapies. In: Lo Re, G., Midiri, M. (eds) Crohn’s Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-23066-5_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-23066-5_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-23065-8

  • Online ISBN: 978-3-319-23066-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation